ERBB2 and in situ carcinoma: Invasive ductal and in situ carcinomas had the highest frequency of HER2/neu overexpression (35.4% and 34.9%, respectively); however, no significant relationship was observed between the type of cancer and HER2/neu overexpression (Fisher exact test, P = 0.63).